Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tislelizumab · Tevimbra, BGBA-317

Monoclonal antibody · Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Beigene

Approved FDA, Mar 2024
1 Registered trials

What is Tislelizumab?

Tislelizumab is a monoclonal antibody that binds PD-1 on T cells and blocks its interaction with the ligands PD-L1 and PD-L2, releasing PD-1-mediated inhibition of anti-tumor immune responses.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Tevimbra, BGBA-317
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1), PD-L1 (CD274) (binding partner it blocks), PD-L2 (PDCD1LG2) (binding partner it blocks)
Mechanism
Antagonist of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1/PD-L1 immune checkpoint signaling, T-cell activation
Therapy area
Oncology
Developer
Beigene
In trials of
IBRX
FDA status
Approved as Tevimbra (March 13, 2024), BLA761232 · FDA label
UNII
0KVO411B3N

✅ FDA-approved uses

From the indications section of the FDA label (version of Sep 1, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06745908 Phase 3 NSCLC Stage IV Recruiting IBRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

NSCLC Stage IV

Other drugs acting on PDCD1

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.